Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. [electronic resource]
Producer: 19990812Description: 3442-50 p. digitalISSN:- 0008-5472
- Adenosine Triphosphate -- metabolism
- Amino Acid Sequence
- Amino Acid Substitution
- Amsacrine -- pharmacology
- Animals
- Antineoplastic Agents -- chemistry
- Binding Sites
- CHO Cells
- Carcinoma, Small Cell -- drug therapy
- Catalysis -- drug effects
- Consensus Sequence
- Cricetinae
- Cricetulus
- DNA Damage
- DNA Mutational Analysis
- DNA Topoisomerases, Type II -- genetics
- DNA, Neoplasm -- genetics
- DNA, Single-Stranded -- genetics
- Drug Resistance, Neoplasm -- genetics
- Enzyme Inhibitors -- pharmacology
- Etoposide -- pharmacology
- Humans
- Lung Neoplasms -- drug therapy
- Molecular Sequence Data
- Mutagenesis, Site-Directed
- Point Mutation
- Protein Isoforms -- antagonists & inhibitors
- Razoxane -- chemistry
- Recombinant Fusion Proteins -- metabolism
- Saccharomyces cerevisiae -- genetics
- Structure-Activity Relationship
- Thiobarbiturates -- pharmacology
- Topoisomerase II Inhibitors
- Tumor Stem Cell Assay
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.